Old Web
English
Sign In
Acemap
>
authorDetail
>
Daniel E. Zak
Daniel E. Zak
Seattle Genetics
Immunology
Nivolumab
Brentuximab vedotin
Oncology
Medicine
3
Papers
20
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study
2019
Blood
Alison J. Moskowitz
Ranjana H. Advani
Nancy L. Bartlett
Julie M. Vose
Radhakrishnan Ramchandren
Tatyana Feldman
Ann S. LaCasce
Beth A. Christian
Stephen M. Ansell
Craig H. Moskowitz
Lisa Brown
David Taft
Sahar Ansari
Daniel E. Zak
Mariana Sacchi
Thomas Manley
Alex F. Herrera
Show All
Source
Cite
Save
Citations (14)
Baseline Tumor Transcriptome Characteristics Associated with the Response of Relapsed/Refractory Hodgkin Lymphoma Patients to Brentuximab Vedotin in Combination with Nivolumab
2018
Blood
Daniel E. Zak
Carol Anne Ogden
Alex F. Herrera
Mariana Sacchi
Matt Onsum
Show All
Source
Cite
Save
Citations (0)
Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing)
2018
Blood
Ranjana H. Advani
Alison J. Moskowitz
Nancy L. Bartlett
Julie M. Vose
Radhakrishnan Ramchandren
Tatyana Feldman
Ann S. LaCasce
Beth A. Christian
Stephen Maxted Ansell
Craig H. Moskowitz
Keenan Fenton
Carol Anne Ogden
David Taft
Daniel E. Zak
Mariana Sacchi
Faith Galderisi
Alex F. Herrera
Show All
Source
Cite
Save
Citations (6)
1